While several companies got some positive news by bringing their products to the US FDA, Alkermes PLC, Teva Pharmaceutical Industries Ltd. and Celltrion Inc. ran into agency roadblocks to highlight the bad news of the week.
FDA handed Alkermes a refuse-to-file (RTF) letter for its major depressive disorder (MDD) drug ALKS 5461, citing a lack of...








